ArticleScientific reports2019

Cost-effectiveness of first-line versus delayed use of combination dapagliflozin and metformin in patients with type 2 diabetes.

Ken Lee Chin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.